Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $64,443.60 in Stock

Key Points

• CEO Abraham Ceesay sold 2,210 shares of Rapport Therapeutics at an average price of $29.16, generating $64,443.60. He retained 450,035 shares, worth approximately $13.12 million, after the transaction.
• Rapport shares fell to $25.93 and remain well below their 52-week high of $52.93. The company recently missed quarterly EPS expectations and is forecast to post a full-year loss of about $4.09 per share.
• Despite the insider sale and ongoing losses, analysts maintain a broadly bullish outlook following positive Phase 2 results for RAP-219 in bipolar mania; the consensus rating is “Buy” with an average price target of $68.36.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 2,210 shares of the business's stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $29.16, for a total transaction of $64,443.60. Following the completion of the transaction, the chief executive officer owned 450,035 shares in the company, valued at $13,123,020.60. The trade was a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Abraham Ceesay also recently made the following trade(s):

• On Wednesday, October 7th, Abraham Ceesay sold 1,147 shares of Rapport Therapeutics stock. The shares were sold at an average price of $30.66, for a total transaction of $35,167.02.
• On Tuesday, October 6th, Abraham Ceesay sold 3,375 shares of Rapport Therapeutics stock. The shares were sold at an average price of $32.03, for a total transaction of $108,101.25.
• On Wednesday, September 23rd, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $39.17, for a total transaction of $86,565.70.
• On Tuesday, September 8th, Abraham Ceesay sold 8,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $45.61, for a total value of $374,458.10.
• On Tuesday, August 25th, Abraham Ceesay sold 18,921 shares of Rapport Therapeutics stock. The shares were sold at an average price of $49.57, for a total value of $937,913.97.
• On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The stock was sold at an average price of $48.01, for a total value of $1,390,273.58.
• On Monday, August 10th, Abraham Ceesay sold 22,541 shares of Rapport Therapeutics stock. The shares were sold at an average price of $46.26, for a total value of $1,042,746.66.
• On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $42.11, for a total value of $93,063.10.

Rapport Therapeutics Stock Performance

Shares of NASDAQ RAPP traded down $0.60 during mid-day trading on Friday, reaching $25.93. 1,180,713 shares of the company's stock were exchanged, compared to its average volume of 410,900. The company's 50-day moving average is $39.44 and its 200-day moving average is $39.02. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -8.53 and a beta of 1.22. Rapport Therapeutics, Inc. has a 52-week low of $23.75 and a 52-week high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, equities analysts predict that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Rapport Therapeutics News Summary

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 achieved both Phase 2 endpoints in bipolar mania. The drug produced statistically significant placebo-adjusted improvements in mania measures, and Rapport plans to advance it into Phase 3. The results could substantially expand RAP-219’s market opportunity beyond epilepsy. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain bullish and several raised price targets. JonesTrading increased its target to $82, BTIG Research to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The average analyst target is approximately $68.36, implying substantial upside from recent levels. BTIG Research price target increase
• Positive Sentiment: Company insiders made roughly $1.57 million of open-market purchases. CFO Troy Ignelzi bought 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young and Paul Silva also purchased shares. The concentrated buying may signal management confidence after the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: A valuation analysis argues that RAPP could be approximately 62% below fair value following the Phase 2 data, supporting the bullish case but relying on assumptions about Phase 3 success, approval and future commercialization. Rapport Therapeutics fair value analysis
• Negative Sentiment: Investors still face substantial execution risk. Commentary suggested some portions of the bipolar-mania data narrowly met expectations, potentially limiting enthusiasm after the initial rally. Rapport is also unprofitable, recently missed quarterly EPS estimates and is forecast to post a full-year loss of about $4.09 per share. The shares remain far below their 52-week high and below their 50-day and 200-day moving averages. Rapport Therapeutics bipolar data analysis

Hedge Funds Weigh In On Rapport Therapeutics

Institutional investors have recently bought and sold shares of the company. TRV GP V LLC purchased a new stake in Rapport Therapeutics during the second quarter worth about $261,709,477. ARCH Venture Management LLC acquired a new stake in shares of Rapport Therapeutics during the second quarter worth about $155,376,512. BlackRock Inc. purchased a new position in shares of Rapport Therapeutics in the second quarter valued at approximately $112,500,000. Johnson & Johnson purchased a new position in shares of Rapport Therapeutics in the second quarter valued at approximately $74,360,823. Finally, TRV GP VI LLC purchased a new position in shares of Rapport Therapeutics in the second quarter valued at approximately $40,387,314.

Analyst Ratings Changes

RAPP has been the topic of a number of research analyst reports. Raymond James Financial reissued a "strong-buy" rating and issued a $86.00 price target on shares of Rapport Therapeutics in a research note on Tuesday. UBS Group began coverage on shares of Rapport Therapeutics in a research report on Thursday, October 15th. They set a "buy" rating and a $71.00 price objective for the company. Wall Street Zen downgraded shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Rapport Therapeutics in a research report on Thursday, October 15th. Finally, BTIG Research upped their price target on Rapport Therapeutics from $75.00 to $89.00 and gave the stock a "buy" rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $68.36.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company's approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport's lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.